190 related articles for article (PubMed ID: 16322321)
1. Emerging role of the endothelin axis in ovarian tumor progression.
Bagnato A; Spinella F; Rosanò L
Endocr Relat Cancer; 2005 Dec; 12(4):761-72. PubMed ID: 16322321
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
6. The endothelin axis in cancer.
Bagnato A; Rosanò L
Int J Biochem Cell Biol; 2008; 40(8):1443-51. PubMed ID: 18325824
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
8. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications.
Herrmann E; Bögemann M; Bierer S; Eltze E; Hertle L; Wülfing C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):73-81. PubMed ID: 16375646
[TBL] [Abstract][Full Text] [Related]
9. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
Rosanò L; Di Castro V; Spinella F; Decandia S; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1132-5. PubMed ID: 16741063
[TBL] [Abstract][Full Text] [Related]
10. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.
Bagnato A; Spinella F; Rosanò L
Can J Physiol Pharmacol; 2008 Aug; 86(8):473-84. PubMed ID: 18758494
[TBL] [Abstract][Full Text] [Related]
11. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
Growcott JW
Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.
Spinella F; Rosanò L; Decandia S; Di Castro V; Albini A; Elia G; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1123-7. PubMed ID: 16741061
[TBL] [Abstract][Full Text] [Related]
14. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
15. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells.
Bagnato A; Tecce R; Moretti C; Di Castro V; Spergel D; Catt KJ
Clin Cancer Res; 1995 Sep; 1(9):1059-66. PubMed ID: 9816080
[TBL] [Abstract][Full Text] [Related]
16. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.
Spinella F; Rosanò L; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Feb; 67(4):1725-34. PubMed ID: 17308114
[TBL] [Abstract][Full Text] [Related]
17. Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.
Lössner D; Abou-Ajram C; Benge A; Reuning U
Int J Biochem Cell Biol; 2008; 40(12):2746-61. PubMed ID: 18577466
[TBL] [Abstract][Full Text] [Related]
18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
19. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
Salani D; Rosanò L; Di Castro V; Spinella F; Venuti A; Padley RJ; Nicotra MR; Natali PG; Bagnato A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():318S-321S. PubMed ID: 12193113
[TBL] [Abstract][Full Text] [Related]
20. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.
Li HZ; Wang Y; Gao Y; Shao J; Zhao XL; Deng WM; Liu YX; Yang J; Yao Z
Mol Cancer Res; 2008 Jun; 6(6):917-28. PubMed ID: 18567796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
